CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Rapid monitoring of biomarkers in postoperative care

Cel

Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012. The frequency of complications after surgery is relatively high, but rapid and safe monitoring methods are missing.

MD Biomedical AB has addressed this need and developed a radically new and innovative piece of medical equipment that is gently attached on the surface of the bowel for sampling of biomakers. This makes it possible to detect complications within minutes, at an early stage of illness, and long before patient systemic indications.

The possibility of rapid counteractions improves the treatment of the patient and save health care costs.

The feasibility study comprises one work package divided in 6 tasks and shall in measurable terms assess the functional, medical, economic, and environmental effects and the deliverable is a feasibility report including a business plan.

Zaproszenie do składania wniosków

H2020-SMEInst-2014-2015

Zobacz inne projekty w ramach tego zaproszenia

Szczegółowe działanie

H2020-SMEINST-1-2014

Koordynator

MD BIOMEDICAL AB
Wkład UE netto
€ 50 000,00
Adres
PO POX 7995
90719 UMEA
Szwecja

Zobacz na mapie

MŚP

Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.

Tak
Region
Norra Sverige Övre Norrland Västerbottens län
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
€ 71 429,00